Effect of liver disease on dextromethorphan oxidation capacity and phenotype: a study in 107 patients.

MLA

Larrey, D., et al. “Effect of Liver Disease on Dextromethorphan Oxidation Capacity and Phenotype: A Study in 107 Patients.” British Journal of Clinical Pharmacology, vol. 28, no. 3, Sept. 1989, pp. 297–304. EBSCOhost, https://doi.org/10.1111/j.1365-2125.1989.tb05430.x.

APA

Larrey, D., Babany, G., Tinel, M., Freneaux, E., Amouyal, G., Habersetzer, F., Letteron, P., & Pessayre, D. (1989). Effect of liver disease on dextromethorphan oxidation capacity and phenotype: a study in 107 patients. British Journal of Clinical Pharmacology, 28(3), 297–304. https://doi.org/10.1111/j.1365-2125.1989.tb05430.x

Chicago

Larrey, D., G. Babany, M. Tinel, E. Freneaux, G. Amouyal, F. Habersetzer, P. Letteron, and D. Pessayre. 1989. “Effect of Liver Disease on Dextromethorphan Oxidation Capacity and Phenotype: A Study in 107 Patients.” British Journal of Clinical Pharmacology 28 (3): 297–304. doi:10.1111/j.1365-2125.1989.tb05430.x.